A method for constructing hafft1 cells

Abstract

The invention belongs to the field of biotechnology, and in particular relates to a method for constructing HAFFT1 cells. In this method, cells stimulated by small molecule-modified polypeptides are transformed with TCR-T technology, and the transformed T cells are then knocked out immunosuppressive targets, which accurately protects specific killer T cells from in vivo. Inhibition increases the killing power of T cells to tumor cells. The proportion of specific T cells (TCR+) recognizing tumor antigens in cells transformed by the HAFFT1 program was over 80%.

Description

Technical field: [0001] The invention belongs to the field of biotechnology, and in particular relates to a method for constructing HAFFT1 cells. Background technique: [0002] At present, in terms of tumor-specific immunotherapy, the existing LAK, DC, CIK, and DC-CIK cells and methods have basically been proved to be ineffective, while NK, CAR-NK, TIL and other cell technologies have yet to mature. CAR- T cells also have shortcomings in safety and solid tumor therapy. [0003] In the prior art, DCs are generally modified to present T cells to produce specific killing. Some laboratories are trying to use viruses as vectors to transfect and present T cells to induce specific killing of T cells. We have also used mutant hybrid peptides to directly stimulate PBMCs to induce T cells. There are also laboratories using TCR-T technology to target the presentation of MAGE A3 antigen. [0004] The above treatment methods are immature, especially the in vitro induction of DC cells...

AI Technical Summary

Problems solved by technology

[0005] None of the above schemes consider the self-protection technology of T cells, so that a small number of specific T cells directly face the powerful tumor microenvironment

Images